This site is intended for
US
Healthcare Professionals only.

For Patients
 

CSF1R

CSF1R pathway expressed on an inactive T cell and tumor-associated macrophage diagram

Colony-stimulating factor 1 receptor (CSF1R) regulates macrophage differentiation and function and stimulates the development of tumor associated macrophages (TAMs). Inhibition of CSF1R may deplete TAMs and boost antitumor immunity.

  • CSF1R is a cell-surface receptor expressed by macrophages and other cells of the myeloid lineage1
    • CSF1 is a ligand for CSF1R2
    • IL-34 is another ligand for CSF1R and it is implicated in microglia regulation in the central nervous system3
  • The CSF1/CSF1R pathway is a dominant regulator of macrophage differentiation and function2
  • In preclinical studies, CSF1R blockade, depriving CSF1 of its target receptor, resulted in TAM depletion and improved T-cell responses7,8
  • In addition, the blockade of CSF1R in combination with other checkpoint pathways may improve T-cell function and enhance antitumor activity5,7,9
Thumbnail for the How Does CSF1R Stimulate Immunosuppression? video Thumbnail for the How Does CSF1R Stimulate Immunosuppression? video

How does CSF1R stimulate immunosuppression?

Learn about CSF1R and the development and survival of TAMs

Watch video

Get I-O Resources

Order or download
educational tools for your
patients and practice

See all resources

Clinical Trials

Learn more about our
current clinical trials

Learn more

REFERENCES–CSF1R

1. Stanley ER, Chitu V. CSF-1 receptor signaling in myeloid cells. Cold Spring Harb Perspect Biol. 2014;6(6):a021857. doi:10.1101/cshperspect.a021857. 2. Richardsen E, Uglehus RD, Johnsen SH, Busund LT. Macrophage-colony stimulating factor (CSF1) predicts breast cancer progression and mortality. Anticancer Res. 2015;35(2):865-874. 3. Nandi S, Gokhan S, Dai X-M, et al. The CSF-1 receptor ligands IL-34 and CSF-1 exhibit distinct developmental brain expression patterns and regulate neural progenitor cell maintenance and maturation. Dev Biol. 2012;367(2):100-113. 4. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014;41(1):49-61. 5. Zhu Y, Knolhoff BL, Meyer MA, et al. CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. Cancer Res. 2014;74(18):5057-5069. 6. Yang L, Wu Q, Xu L, et al. Increased expression of colony stimulating factor-1 is a predictor of poor prognosis in patients with clear-cell renal cell carcinoma. BMC Cancer. 2015. doi:10.1186/s12885-015-1076-5. 7. Ries CH, Cannarile MA, Hoves S, et al. Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy. Cancer Cell. 2014;25(6):846-859. 8. Mitchem JB, Brennan DJ, Knolhoff BL, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2012;73(3):1128-1141. 9. Neubert NJ, Schmittnaegel M, Bordry N, Nassiri S, Wald N, Martignier C, Tillé L, Homicsko K, Damsky W, Maby-El Hajjami H, Klaman I. T cell–induced CSF1 promotes melanoma resistance to PD1 blockade. Science translational medicine. 2018;10(436):eaan3311.